Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
申请人:Robinson W. Edward
公开号:US20050049242A1
公开(公告)日:2005-03-03
The present invention includes a group of novel compounds that are demonstrated to potently and selectively inhibit HIV integrase (IN) activity in vitro and to potently inhibit HIV replication in live, cultured cells at non-toxic concentrations. The novel compounds disclosed include 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-L-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-L-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-L-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-L-serine, bis-dicaffeoyl-L-isoserine and 1,4-dicaffeoyl-L-lysine. Tests of integrase inhibitors with 2′,3′-dideoxycytidine, zidovudine and nelfinavir (protease inhibitor) indicated a potent synergy against reverse transcriptase inhibitor resistant virus. The potential benefit from the addition of integrase inhibitors to combination drug therapies is significant.
本发明包括一组新颖的化合物,已被证明能够在体外强力且选择性地抑制HIV整合酶(IN)活性,并在非毒性浓度下有效抑制活体培养细胞中的HIV复制。所披露的新颖化合物包括2,3-二(3,4-二羟基-二羟基二羟基肉桂酰)-L-酒石酸,2,3-二(3,4-二羟基苯甲酰)-L-酒石酸,2,3-二(3,4-二羟基苯乙酰)-L-酒石酸,2,3-二(3,4,5-三羟基苯甲酰)-L-酒石酸,2,3-二咖啡酰二氨基丙酸,1,2-二咖啡酰-L-甘油酸,双-3,4-二咖啡酰二氨基苯甲酸,二-3,4-二羟基苯乙烯琥珀酸,二-3,4-二羟基二羟基苯乙烯琥珀酸,2,3-二咖啡酰-L-丝氨酸,双咖啡酰-L-异丝氨酸和1,4-二咖啡酰-L-赖氨酸。对整合酶抑制剂与2′,3′-二脱氧胞苷、阿司匹林和奈非那韦(蛋白酶抑制剂)的测试表明,对逆转录酶抑制剂耐药病毒具有强大的协同作用。将整合酶抑制剂添加到联合药物疗法中的潜在益处是显著的。